annual FCF:
$4.45B+$2.82B(+172.44%)Summary
- As of today (May 23, 2025), TAK annual free cash flow is $4.45 billion, with the most recent change of +$2.82 billion (+172.44%) on March 1, 2025.
- During the last 3 years, TAK annual FCF has fallen by -$3.90 billion (-46.71%).
- TAK annual FCF is now -46.71% below its all-time high of $8.35 billion, reached on March 31, 2022.
Performance
TAK Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
$854.77M-$1.25B(-59.40%)Summary
- As of today (May 23, 2025), TAK quarterly free cash flow is $854.77 million, with the most recent change of -$1.25 billion (-59.40%) on March 1, 2025.
- Over the past year, TAK quarterly FCF has dropped by -$633.39 million (-42.56%).
- TAK quarterly FCF is now -71.04% below its all-time high of $2.95 billion, reached on March 31, 2022.
Performance
TAK quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$4.45B-$633.39M(-12.46%)Summary
- As of today (May 23, 2025), TAK TTM free cash flow is $4.45 billion, with the most recent change of -$633.39 million (-12.46%) on March 1, 2025.
- Over the past year, TAK TTM FCF has increased by +$2.82 billion (+172.44%).
- TAK TTM FCF is now -46.71% below its all-time high of $8.35 billion, reached on March 31, 2022.
Performance
TAK TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
TAK Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +172.4% | -42.6% | +172.4% |
| 3 y3 years | -46.7% | -71.0% | -46.7% |
| 5 y5 years | +7.0% | -24.3% | +7.0% |
TAK Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -46.7% | +172.4% | -71.0% | +166.3% | -46.7% | +645.9% |
| 5 y | 5-year | -46.7% | +172.4% | -71.0% | +166.3% | -46.7% | +645.9% |
| alltime | all time | -46.7% | +999.2% | -71.0% | +161.1% | -46.7% | +521.8% |
TAK Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | $4.45B(+172.4%) | $854.77M(-59.4%) | $4.45B(-12.5%) |
| Dec 2024 | - | $2.11B(+64.6%) | $5.08B(+47.2%) |
| Sep 2024 | - | $1.28B(+513.6%) | $3.45B(+10.3%) |
| Jun 2024 | - | $208.52M(-86.0%) | $3.13B(+91.7%) |
| Mar 2024 | $1.63B(-35.8%) | $1.49B(+212.2%) | $1.63B(-300.4%) |
| Dec 2023 | - | $476.74M(-50.2%) | -$814.80M(-180.8%) |
| Sep 2023 | - | $956.59M(-174.2%) | $1.01B(-26.1%) |
| Jun 2023 | - | -$1.29B(+34.3%) | $1.36B(-46.4%) |
| Mar 2023 | $2.54B(-69.5%) | -$959.41M(-141.7%) | $2.54B(-60.6%) |
| Dec 2022 | - | $2.30B(+75.2%) | $6.45B(-3.6%) |
| Sep 2022 | - | $1.31B(-1303.2%) | $6.70B(-5.7%) |
| Jun 2022 | - | -$109.09M(-103.7%) | $7.10B(-14.9%) |
| Mar 2022 | $8.35B(+14.3%) | $2.95B(+16.2%) | $8.35B(+3.7%) |
| Dec 2021 | - | $2.54B(+48.0%) | $8.05B(+11.4%) |
| Sep 2021 | - | $1.72B(+50.9%) | $7.23B(-3.2%) |
| Jun 2021 | - | $1.14B(-57.2%) | $7.46B(+2.2%) |
| Mar 2021 | $7.31B(+75.7%) | $2.66B(+54.8%) | $7.31B(+26.5%) |
| Dec 2020 | - | $1.72B(-12.1%) | $5.78B(+25.0%) |
| Sep 2020 | - | $1.95B(+99.3%) | $4.62B(+4.4%) |
| Jun 2020 | - | $979.32M(-13.3%) | $4.43B(+6.5%) |
| Mar 2020 | $4.16B(+137.2%) | $1.13B(+100.6%) | $4.16B(+12.2%) |
| Dec 2019 | - | $562.75M(-68.0%) | $3.71B(+0.5%) |
| Sep 2019 | - | $1.76B(+148.5%) | $3.69B(+52.8%) |
| Jun 2019 | - | $707.93M(+4.7%) | $2.41B(+37.7%) |
| Mar 2019 | $1.75B(-22.2%) | $676.10M(+24.3%) | $1.75B(-12.8%) |
| Dec 2018 | - | $544.05M(+12.1%) | $2.01B(-1.0%) |
| Sep 2018 | - | $485.30M(+916.4%) | $2.03B(+8.1%) |
| Jun 2018 | - | $47.75M(-94.9%) | $1.88B(-16.6%) |
| Mar 2018 | $2.25B(+63.1%) | $933.11M(+65.5%) | $2.25B(+6.3%) |
| Dec 2017 | - | $563.90M(+69.2%) | $2.12B(+50.5%) |
| Sep 2017 | - | $333.21M(-21.1%) | $1.41B(-4.0%) |
| Jun 2017 | - | $422.46M(-47.1%) | $1.47B(+6.2%) |
| Mar 2017 | $1.38B | $798.90M(-644.4%) | $1.38B(-269.0%) |
| Dec 2016 | - | -$146.74M(-137.4%) | -$816.88M(+268.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2016 | - | $392.19M(+16.5%) | -$221.51M(+20.9%) |
| Jun 2016 | - | $336.58M(-124.1%) | -$183.21M(-63.0%) |
| Mar 2016 | -$494.72M(-173.3%) | -$1.40B(-411.8%) | -$494.72M(-148.4%) |
| Dec 2015 | - | $448.64M(+4.2%) | $1.02B(+15.5%) |
| Sep 2015 | - | $430.48M(+1617.2%) | $884.98M(-9.1%) |
| Jun 2015 | - | $25.07M(-78.7%) | $973.73M(+44.3%) |
| Mar 2015 | $674.86M(-3.7%) | $117.69M(-62.2%) | $674.86M(-51.3%) |
| Dec 2014 | - | $311.74M(-40.0%) | $1.39B(+2.1%) |
| Sep 2014 | - | $519.23M(-289.6%) | $1.36B(-8.4%) |
| Jun 2014 | - | -$273.80M(-133.0%) | $1.48B(+111.4%) |
| Mar 2014 | $700.90M(-73.7%) | $829.11M(+193.2%) | $700.90M(-646.7%) |
| Dec 2013 | - | $282.76M(-56.1%) | -$128.20M(-68.8%) |
| Sep 2013 | - | $643.77M(-161.0%) | -$410.96M(-61.0%) |
| Jun 2013 | - | -$1.05B(-189.2%) | -$1.05B(-144.8%) |
| Mar 2013 | $2.67B(-20.8%) | - | - |
| Mar 2012 | $3.36B(+42.9%) | - | - |
| Mar 2011 | $2.36B(-25.7%) | $1.18B(+176.1%) | $2.36B(+20.6%) |
| Dec 2010 | - | $428.34M(-49.4%) | $1.95B(-10.2%) |
| Sep 2010 | - | $845.79M(-930.1%) | $2.18B(-8.3%) |
| Jun 2010 | - | -$101.89M(-113.0%) | $2.37B(-25.2%) |
| Mar 2010 | $3.17B(+9.9%) | $781.13M(+20.2%) | $3.17B(+32.7%) |
| Dec 2009 | - | $650.04M(-37.7%) | $2.39B(+37.4%) |
| Sep 2009 | - | $1.04B(+49.7%) | $1.74B(+149.7%) |
| Jun 2009 | - | $696.73M | $696.73M |
| Mar 2009 | $2.88B(+26.5%) | - | - |
| Mar 2008 | $2.28B(+48.0%) | - | - |
| Mar 2007 | $1.54B(-49.0%) | - | - |
| Mar 2006 | $3.02B(+34.0%) | - | - |
| Mar 2005 | $2.25B(-1.1%) | - | - |
| Mar 2004 | $2.28B(+20.7%) | - | - |
| Mar 2003 | $1.89B(+16.2%) | - | - |
| Mar 2002 | $1.63B(-3.4%) | - | - |
| Mar 2001 | $1.68B(+51.1%) | - | - |
| Mar 2000 | $1.11B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual free cash flow?
- What is the all time high annual FCF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual FCF year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly free cash flow?
- What is the all time high quarterly FCF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly FCF year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM free cash flow?
- What is the all time high TTM FCF for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM FCF year-on-year change?
What is Takeda Pharmaceutical Company Limited annual free cash flow?
The current annual FCF of TAK is $4.45B
What is the all time high annual FCF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual free cash flow is $8.35B
What is Takeda Pharmaceutical Company Limited annual FCF year-on-year change?
Over the past year, TAK annual free cash flow has changed by +$2.82B (+172.44%)
What is Takeda Pharmaceutical Company Limited quarterly free cash flow?
The current quarterly FCF of TAK is $854.77M
What is the all time high quarterly FCF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly free cash flow is $2.95B
What is Takeda Pharmaceutical Company Limited quarterly FCF year-on-year change?
Over the past year, TAK quarterly free cash flow has changed by -$633.39M (-42.56%)
What is Takeda Pharmaceutical Company Limited TTM free cash flow?
The current TTM FCF of TAK is $4.45B
What is the all time high TTM FCF for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM free cash flow is $8.35B
What is Takeda Pharmaceutical Company Limited TTM FCF year-on-year change?
Over the past year, TAK TTM free cash flow has changed by +$2.82B (+172.44%)